|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01192802 |
|
Date of registration:
|
31/08/2010 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Efficacy of Albendazole to Treat Intestinal Helminths and Its Effect on Gut Microflora
|
|
Scientific title:
|
Effect of Intestinal Helminths on Gut Microflora |
|
Date of first enrolment:
|
August 2010 |
|
Target sample size:
|
200 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT01192802 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
Gabon
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- presence of intestinal helminths eggs in the stool
Exclusion Criteria:
- allergy to imidazole derivate
- No intestinal helminths
Age minimum:
4 Years
Age maximum:
14 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Intestinal Diseases
|
|
Helminthiasis
|
|
Intervention(s)
|
|
Drug: albendazole
|
|
Primary Outcome(s)
|
|
parasite cleared and reduced up to 80% at day 42
[Time Frame: 42 days]
|
|
Secondary Outcome(s)
|
|
Prevalence of major gut bacteria
[Time Frame: 42 days]
|
|
Secondary ID(s)
|
|
Albendazole-001
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|